

## Urokinase Market to Reach \$3.1 Billion, Globally, by 2033 at 5.7% CAGR

The global urokinase market size was valued at \$1.8 billion in 2023, and is projected to reach \$3.1 billion by 2033, growing at a CAGR of 5.7% from 2024 to 2033

PORTLAND, OR, UNITED STATES,
December 11, 2024 /
EINPresswire.com/ -- Allied Market
Research published a report, titled,
"<u>Urokinase Market</u> by Type (Urokinase
Powder and Urokinase Solution), and
End User (Hospital and Clinics): Global
Opportunity Analysis and Industry
Forecast, 2024-2033". According to the



report, the urokinase market was valued at \$1.8 billion in 2023, and is estimated to reach \$3.1 billion by 2033, growing at a CAGR of 5.7% from 2024 to 2033.

 $\ \, 0000000\ \, 000000\ \, 0000\ \, 00\ \, 000000\ \, -$ 

https://www.alliedmarketresearch.com/request-sample/A324534

## Prime Determinants of Growth

The key factors driving the growth of the urokinase market include rise in prevalence of cardiovascular diseases and surge in geriatric population. Cardiovascular diseases, in particular, are a leading cause of mortality globally, often leading to complications such as deep vein thrombosis and pulmonary embolism, which require prompt and effective treatment with thrombolytic agents. Additionally, the aging global population, which is more susceptible to chronic ailments, further exacerbates this demand. The increasing incidence of diabetes also plays a critical role, as patients with diabetes are at a higher risk of developing blood clots, necessitating the use of urokinase to manage these complications.

Segment Highlights

The urokinase solution segment dominated market share in 2023

By type, urokinase solution segment dominated market share in 2023. This is attributed to advantages in terms of ease of administration, precise dosing, and rapid onset of action, which are essential in emergency medical situations.

Hospital segment is expected to register fastest growth during the forecast period

By end user, hospital segment dominated the market share in 2023. This is attributed to the fact hospitals are primary centers for treating acute medical conditions that require urokinase, such as pulmonary embolism, deep vein thrombosis, and acute myocardial infarction. These conditions often necessitate urgent and high-volume use of thrombolytic agents, for which hospitals are best equipped. Additionally, hospitals possess the necessary infrastructure, including intensive care units and advanced diagnostic facilities, to monitor and manage the administration of urokinase and its potential complications.

https://www.alliedmarketresearch.com/urokinase-market/purchase-options

## **Regional Outlook**

In North America, particularly the U.S., the market growth is driven developed healthcare systems, advanced diagnostic technologies, and a high prevalence of cardiovascular diseases and cancer. Europe also shows substantial market growth, driven by a well-established healthcare system and increasing ageing population.

In the Asia-Pacific region, the urokinase market is experiencing rapid expansion. This growth is fueled by rapid urbanization, expanding healthcare access, and rising awareness about cardiovascular health. In addition, government initiatives to improve healthcare infrastructure and affordable healthcare further propel the growth of the market China and India.

Major Key Players -

**NDpharm** 

Wanhua Biochem

Jiangxi Haoran Bio-Pharma

Jiangsu Aidea Pharmaceutical

Techpool, Microbic Biosystems Inc LIVZON

Cadila Healthcare Limited

TAJ Pharmaceuticals Limited

Microbix Biosystems Inc

Syner Medica LTD

ImaRx Therapeutics, Inc

The report provides a detailed analysis of these key players in the global urokinase market. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.

DDD DDDDDDD DDDDDDD DD DDDDDD - https://www.alliedmarketresearch.com/purchase-enguiry/A324534

Frequently Asked Questions?

- Q1. What would be forecast period in the market report?
- Q2. What is the total market value of Urokinase Market report?
- Q3. What is the market value of Urokinase Market in 2033?
- Q4. Which is base year calculated in the Urokinase Market report?
- Q5. What is Urokinase?

About Us -

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data

presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa Allied Market Research +1 800-792-5285 email us here Visit us on social media: Facebook X

This press release can be viewed online at: https://www.einpresswire.com/article/768162243

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.